\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes Missions New European BauhausCall HORIZON-MISS-2024-NEB-01 has closed on 19 September 2024.
93 proposals have been submitted.
The breakdown per call topic is:
HORIZON-MISS-2024-NEB-01 (RIA): 29 proposals
HORIZON-MISS-2024-NEB-02 (IA): 58 proposals
HORIZON-MISS-2024-NEB-03 (CSA): 6 proposals
Evaluation results are expected to be communicated by January 2025.
Source: Funding and Tenders Portal
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
